Alanine variant of the Pro12Ala polymorphism of the PPARγ gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 80, Issue 1, 2008, Pages 139-145

  Malecki, Maciej T ^a   Cyganek, Katarzyna ^a   Mirkiewicz Sieradzka, Barbara ^a   Wolkow, Pawel P ^a   Wanic, Krzysztof ^b   Skupien, Jan ^a   Solnica, Bogdan ^a   Sieradzki, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Gene; PPAR ; Retinopathy

Indexed keywords

ALANINE; CALPAIN 10; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; PROTEIN TYROSINE PHOSPHATASE;

ADULT; AGED; ALLELE; ARTICLE; CALPAIN 10 GENE; DIABETIC RETINOPATHY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PPAR GAMMA GENE; PTPN1 GENE; RISK REDUCTION; STATISTICAL ANALYSIS;

AGED; ALANINE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS;

EID: 40849142513     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.11.001     Document Type: Article

References (48)

1. Harding S., Greenwood R., Aldington S., Gibson J., Owens D., Taylor R., et al. Grading and disease management in national screening for diabetic retinopathy. Diab. Med. 20 (2003) 965-971
2. Hallman D., Huber J., Gonzales V., Klein B., Klein R., and Hanis C. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diab. Care 28 (2005) 116-1163
3. Leslie R., and Pyke D. Diabetic retinopathy in identical twins. Diabetes 31 (1982) 19-21
4. Warpeha K., and Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 17 (2003) 305-311
5. Imperatore G., Hanson R., Pettitt D., Kobes S., Bennett P., and Knowler W. Sip-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 47 (1998) 821-830
6. Stratton I., Kohner E., Aldington S., Turner R., Holman R., Manley S., et al. for UKPDS Group: UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44 (2001) 156-163
7. Singleton R., Smith G., Russell J., and Feldman E. Microvascular complications of impaired glucose tolerance. Diabetes 52 (2003) 2867-2873
8. Steinberg H., and Baron A. Vascular function, insulin resistance and fatty acids. Diabetologia 45 (2002) 623-634
9. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M., and Groop L. The metabolic syndrome influences the risk of chronic complications in patients in type 2 diabetes. Diabetologia 41 (2001) 1148-1154
10. Chaturvedi N., Sjoelie A., Porta M., Aldington S., Fuller J., Songini M., et al., The EURODIAB PCS Group. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. The EURODIAB Prospective Complications Study. Diab. Care 24 (2001) 284-289
11. Zhang L., Krzentowski G., Albert A., and Lefebvre P. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diab. Care 24 (2001) 1275-1279
12. Parvanova A., Iliev I., Fillipponi M., Dimitrov B., Vedovato M., Tiengo A., et al. Insulin Resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with diabetes type 2. J. Clin. Endocrinol. Metab. 89 (2004) 4371-4376
13. Reiter C., Wu X., Sandirasegarane L., Nakamura M., Gilbert K., Singh R., et al. Diabetes reduces basal retinal insulin receptor signalling. Reversal with systemic and local insulin. Diabetes 55 (2006) 1148-1156
14. Deep S., Fajans L., Nemoto M., Pihlajamaki J., Mykkanen J., Kuusisto J., et al. A Pro12Ala substitution in PPAR gamma 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20 (1998) 284-287
15. Baier L., Permana P., Yang X., Pratley R., Hanson R., Shen G., et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J. Clin. Invest. 106 (2000) R69-R73
16. Palmer N., Bento J., Mychaleckyj J., Langefeld C., Campbell J., Norris J., et al. Association of protein tyrosine phosphatase 1B gene polymorphism with measures of glucose homeostasis in Hispanic Americans. The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 53 (2004) 3013-3019
17. Sorimachi H., Ishiura S., and Suzuki K. Structure and physiological function of calpains. Biochem. J. 328 (1997) 721-732
18. Auwerx J. PPARg, the ultimately thrifty gene. Diabetologia 42 (1999) 1033-1049
19. Tontonoz P., Hu E., and Spiegelman B. Stimulation of adipogenesis in fibroblasts by PPARg2, a lipid activated transcription factor. Cell 79 (1994) 1147-1156
20. Goldstein B.J., Bittner-Kowalczyk A., White M.F., and Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrat-1 by protein-tyrosine phosphatase 1B. J. Biol. Chem. 275 (2000) 4283-4289
21. Seely B.L., Staubs P.A., Reichart D.R., Bernhanu P., Milarski K.L., Saltiel A.R., et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45 (1996) 1379-1385
22. Malecki M.T., Moczulski D.K., Klupa T., Wanic K., Cyganek K., Frey J., et al. Homozygous combination of calpain 10 gene haplotypes is associated with type 2 diabetes mellitus in a Polish population. Eur. J. Endocrinol. 146 (2002) 695-699
23. Cyganek K., Mirkiewicz-Sieradzka B., Malecki M.T., Wolkow P., Skupien J., Bobrek J., et al. Clinical risk factors and VDR gene polymorphisms role in diabetic retinopathy in Polish type 2 diabetes patients. Acta Diabetol. 43 (2006) 114-119
24. Aldington S., Kohner E., Meuer S., Klein R., and Sjolie A. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications study. Diabetologia 38 (1995) 437-444
25. Malecki M.T., Frey J., Klupa T., Skupien J., Walus M., Mlynarski W., et al. The Pro12Ala polymorphism of PPARgamma2 gene and susceptibility to type 2 diabetes mellitus in a Polish population. Diab. Res. Clin. Pract. 62 (2003) 105-111
26. Wanic K., Malecki M.T., Klupa T., Warram J.H., Sieradzki J., and Krolewski A.S. Polymorphisms in the gene encoding protein tyrosine phosphatase 1B (PTPN1) and risk of type 2 diabetes in a Polish population. Diab. Med. 24 (2007) 650-655
27. Rogus J., Warram H., and Krolewski A.S. Genetic studies of diabetic complications. The overlooked importance of diabetes duration before complication onset. Diabetes 51 (2002) 1655-2002
28. Stefan N., Fritsche A., Häring H., and Stumvoll M. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor g2 gene. Diabetes 50 (2001) 1143-1148
29. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., et al. The Pro12Ala polymorphism in PPAR gamma 2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 271 (2000) 212-216
30. Muller Y., Bogardus C., Beamer B., Shuldiner A., and Baier L. A functional variant in the peroxisome proliferator-activated receptor gamma 2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 52 (2003) 1864-1871
31. Ek J., Andersen G., Urhammer S., Hansen L., Carstensen B., Borch-Johnsen K., et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 44 (2001) 1170-1176
32. Mori H., Ikegami H., Kawaguchi Y., Seino S., Yokoi N., Takeda J., et al. The Pro12Ala substitution in PPAR gamma is associated with resistance to development of diabetes in general population: possible involvement in impairments of insulin secretion in individuals with type 2 diabetes. Diabetes 50 (2001) 891-894
33. Miles P., Barak Y., He W., Evans R., and Olefsky J. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105 (2000) 287-292
34. Altshuler D., Hirschhorn J., Klannemark M., Lindgren C., Vohl M., Nemesh J., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
35. Ardlie K., Lunetta K., and Seielstad M. Testing for population subdivision and association in four case-control studies. Am. J. Hum. Genet. 71 (2002) 3004-3111
36. Lindi V., Uusitupa M., Lindstrom J., Louheranta A., Eriksson J., Hamalainene H., et al. Finnish Diabetes Prevention Study: Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51 (2002) 2581-2586
37. Mancini F., Vaccaro O., Sabatino L., Tufano A., Rivellese A., Riccardi G., et al. Pro12Ala substitution in peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 48 (1999) 1466-1468
38. Stumvoll M., Wahl H., Loblein K., Becker R., Machicao F., Jacob S., et al. Pro 12Ala polymorphism in the peroxisome proliferator-activated receptor γ2 gene is associated with increased antilipolitic insulin sensitivity. Diabetes 50 (2001) 876-881
39. Memisoglu A., Hu F., Hankinson S., Liu S., Meigs J., Altshuler D., et al. Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and type 2 diabetes. Diab. Care 26 (2003) 2915-2917
40. Herrmann S.M., Ringel J., Wang J., Staessen J., and Brand E. Peroxisome proliferator-activated receptor-g2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. The Berlin Diabetes mellitus (BeDiaM) Study. Diabetes 51 (2002) 2653-2657
41. Caramori L., Canani L., Costa L., and Gross J. The human peroxisome proliferator-activated receptor-g2 (PPAR-g2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52 (2003) 3010-3013
42. Petrovic M., Kunej T., Peterlin B., Dovc P., and Petrovic D. Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-γ2 coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARg gene is not. Diab. Metab. Res. Rev. 21 (2005) 470-474
43. Shore A., Evans J., Frayling T., Clark P., Lee B., Horikawa Y., et al. Association of the calpain-10 gene with microvascular function. Diabetologia 45 (2002) 899-904
44. Goodarzi M., Taylor K., Guo X., Quinones M., Cui J., Li Y., et al. Association of the diabetes gene calpain-10 with subclinical atherosclerosis. The Mexican-American Coronary Artery Disease Study. Diabetes 54 (2005) 1228-1232
45. Burdon K., Bento J., Langefeld C., Campbell J., Carr J., Wagenknecht L., et al. Association of protein tyrosine phosphatase-N1 polymorphisms with coronary calcified plaque in the Diabetes Heart Study. Diabetes 55 (2006) 651-658
46. Altshuler D., Kruglyak L., and Lander E. Genetic polymorphisms and disease. N. Engl. J. Med. 338 (1998) 1626
47. Eid H., Lyberg T., Arnesen H., and Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells. The role of DDAH. Atherosclerosis 194 (2007) e1-8
48. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diab. Care 27 (2004) 765-769